All In Biotech

Drug Trial Radar · NCT07218809

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,100

Planned (sponsor's estimate)

Start

Dec 29, 2025

Primary completion

Nov 17, 2028

Study completion Dec 27, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation; Ventana Medical Systems, Inc
First posted
Oct 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels.

Conditions

  • Epithelial Ovarian Cancer

Interventions

  • AZD5335Drug

    antibody drug conjugate

  • Mirvetuximab Soravtansine (MIRV)Drug

    antibody drug conjugate

  • PaclitaxelDrug

    chemotherapy

  • Pegylated liposomal Doxorubicin (PLD)Drug

    chemotherapy

  • TopotecanDrug

    chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free Survival (PFS)Time frame: Up to approximately 5 years

Locations

299 sites in 24 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama · Recruiting

  • Research Site

    Little Rock, Arkansas · Not yet recruiting

  • Research Site

    La Jolla, California · Not yet recruiting

  • Research Site

    Washington D.C., District of Columbia · Recruiting

  • Research Site

    Fort Lauderdale, Florida · Not yet recruiting

  • Research Site

    Gainesville, Florida · Recruiting

  • Research Site

    Jupiter, Florida · Recruiting

  • Research Site

    Miami, Florida · Recruiting

  • Research Site

    Weston, Florida · Not yet recruiting

  • Research Site

    Chicago, Illinois · Not yet recruiting

  • Research Site

    Evanston, Illinois · Not yet recruiting

  • Research Site

    Peoria, Illinois · Recruiting

  • Research Site

    Urbana, Illinois · Recruiting

  • Research Site

    Fort Wayne, Indiana · Recruiting

  • Research Site

    Indianapolis, Indiana · Recruiting

  • Research Site

    Louisville, Kentucky · Recruiting

  • Research Site

    Towson, Maryland · Recruiting

  • Research Site

    Burlington, Massachusetts · Recruiting

  • Research Site

    Worcester, Massachusetts · Not yet recruiting

  • Research Site

    Minneapolis, Minnesota · Recruiting

  • Research Site

    Springfield, Missouri · Recruiting

  • Research Site

    Billings, Montana · Recruiting

  • Research Site

    Omaha, Nebraska · Recruiting

  • Research Site

    Las Vegas, Nevada · Recruiting

  • Research Site

    Lebanon, New Hampshire · Not yet recruiting

  • Research Site

    Camden, New Jersey · Not yet recruiting

  • Research Site

    The Bronx, New York · Not yet recruiting

  • Research Site

    Chapel Hill, North Carolina · Recruiting

  • Research Site

    Blue Ash, Ohio · Recruiting

  • Research Site

    Dayton, Ohio · Recruiting

  • Research Site

    Sylvania, Ohio · Not yet recruiting

  • Research Site

    Portland, Oregon · Recruiting

  • Research Site

    York, Pennsylvania · Not yet recruiting

  • Research Site

    Germantown, Tennessee · Recruiting

  • Research Site

    San Antonio, Texas · Recruiting

  • Research Site

    Tyler, Texas · Recruiting

  • Research Site

    Salt Lake City, Utah · Withdrawn

  • Research Site

    Fairfax, Virginia · Recruiting

  • Research Site

    Roanoke, Virginia · Recruiting

  • Research Site

    Seattle, Washington · Recruiting

Showing 40 of 299 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.